Drug-labels.com

Wegovy: Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx)
Strength:
0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, 2 mg, 4 mg, 6.8 mg, 9.6 mg
Active ingredient:

Patient Medication Information: uses, side effects, how to take - Wegovy

Serious warnings and precautions box

What WEGOVY® is used for:

For the following indication(s) WEGOVY® has been approved with conditions (NOC/c). This means it has passed Health Canada’s review and can be bought and sold in Canada, but the manufacturer has agreed to complete more studies to make sure the drug works the way it should. For more information, talk to your healthcare professional.

  • WEGOVY® is used to treat metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. It is used to reduce liver damage, such as build-up of fat, inflammation and scar tissue in the liver in adults with MASH.

For the following indication(s) WEGOVY® has been approved without conditions. This means it has passed Health Canada’s review and can be bought and sold in Canada.

  • WEGOVY® is used for chronic weight management in addition to a reduced calorie

Possible Risk of thyroid tumours, including cancer

As part of drug testing, semaglutide, the active ingredient in WEGOVY® was given to rats and mice in long term studies. In these studies, semaglutide caused both rats and mice to develop medullary thyroid tumours, some of which were cancer. It is not known if semaglutide will cause thyroid tumours or a rare type of thyroid cancer called medullary thyroid cancer in people. Do not use WEGOVY® if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC), or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

While taking WEGOVY®, tell your healthcare professional if you get a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath. These may be symptoms of thyroid cancer. You should discuss any safety concerns you have about the use of WEGOVY® with your healthcare professional.

  • diet and increased physical activity in adults, who have:

    • a BMI of 30 kg/m2 or greater (with obesity), or
    • a BMI of 27 kg/m2 and less than 30 kg/m2 (overweight) and weight-related health problems.

*BMI (Body Mass Index) is a measure of your weight in relation to your height. See your healthcare professional to have your BMI measured.

  • WEGOVY® is used for chronic weight management in addition to a reduced calorie diet and increased physical activity in adolescents aged 12 to less than 18 years, who have obesity, as diagnosed by a healthcare professional, and who have not succeeded in weight loss with diet and exercise alone.
  • WEGOVY® is used to reduce the risk of non-fatal heart attacks in adults with a history of heart disease (like a heart attack, stroke or poor blood flow to the limbs) and BMI ≥27 kg/m2.

What is a Notice of Compliance with Conditions (NOC/c)?

A Notice of Compliance with Conditions (NOC/c) is a type of approval to sell a drug in Canada.

Health Canada only gives an NOC/c to a drug that treats, prevents, or helps identify a serious or life-threatening illness. The drug must show promising proof that it works well, is of high quality, and is reasonably safe. Also, the drug must either respond to a serious medical need in Canada, or be much safer than existing treatments.

Drug makers must agree in writing to clearly state on the label that the drug was given an NOC/c, to complete more testing to make sure the drug works the way it should, to actively monitor the drug’s performance after it has been sold, and to report their findings to Health Canada.

How WEGOVY® works:

WEGOVY® is similar to a natural hormone called glucagon-like peptide-1 (GLP-1) that is released from the intestine after a meal. WEGOVY® works by causing you to feel fuller and less hungry. WEGOVY® should be used along with a reduced calorie diet and increased physical activity.

In the liver, WEGOVY® works by slowing down or stopping further liver damage caused by fat build-up and inflammation, and by supporting a reduction of liver scarring.

The ingredients in WEGOVY® are:

Medicinal ingredient: semaglutide

Single-Use Pen

Non-medicinal ingredients: Disodium phosphate dihydrate; Hydrochloric acid; Sodium Chloride; Sodium hydroxide; Water for injection

Multi-Use pen

Non-medicinal ingredients: Disodium phosphate dihydrate; Propylene glycol; Phenol; Hydrochloric acid; Sodium hydroxide; Water for injection

WEGOVY® comes in the following dosage forms:

WEGOVY® is supplied as a clear and colourless solution for injection in a pre-filled pen.

WEGOVY® is available in a carton of 4 single-use, disposable, pre-filled pens delivering doses of either 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg. The 0.25 mg, 0.5 mg and 1 mg pens contain 0.5 mL solution. The 1.7 mg and 2.4 mg pens contain 0.75 mL of solution.

WEGOVY® is available in a carton of 1 multi-use, disposable, pre-filled pen delivering doses of either 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg. The 0.25 mg pen contains 1.5 mL solution. The 0.5 mg pen contains either 1.5 mL or 3 mL of solution. The 1 mg,1.7 mg and 2.4 mg pens contain 3 mL of solution.

Your single-use pen is only to be used once. It comes with:

  • One pre-set dose.
  • A needle cover that hides the built-in needle before, during and after use.
  • Automatic dosing that starts when the needle cover is pressed against your skin as described by your healthcare professional.

Your multi-use pen can be used multiple times. It comes with:

  • Four doses of either 0.25 mg, 0.5 mg, 1 mg, 1.7 mg or 2.4 mg.
  • 4 disposable needles

Do not use WEGOVY® if:

  • You are allergic to semaglutide or any of the other ingredients of this medicine.
  • You or a member of your family has ever had medullary thyroid cancer (MTC).
  • You have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • You are pregnant or breastfeeding.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take WEGOVY®. Talk about any health conditions or problems you may have, including if you:

  • or a member of your family has or has had medullary thyroid carcinoma (MTC), or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • Have type 1 diabetes.
  • Have ever had diabetic ketoacidosis (increased ketones in the blood or urine).
  • Have ever had an allergic reaction to OZEMPIC® or RYBELSUS®.
  • Have a high heart rate (fast pulse).
  • Have ever had an inflamed pancreas (pancreatitis).
  • Are breastfeeding or plan to breastfeed.
  • Are pregnant or plan to become pregnant.
  • Have end stage renal disease.
  • Have gastrointestinal (digestive) problems, including severe vomiting, diarrhea and/or dehydration.
  • Have hepatic (liver) disease.
  • Have diabetic eye disease (diabetic retinopathy).
  • Have heart failure.
  • Have ever had gallbladder disease.
  • Have ever attempted suicide, or had suicidal thoughts or depression.
  • Have had bariatric (weight loss) surgery.

Other warnings you should know about:

  • Cardiovascular

    • WEGOVY® may increase heart rate and could cause changes known as PR prolongation, which are detected by electrocardiogram (ECG) tracings. Increased heart rate is the same as a faster pulse. These heart rhythm changes are more likely if you have heart disease, or if you are taking certain other drugs. It is important to follow your healthcare professional’s advice about the dose of WEGOVY® or about any special tests that you may need. See ‘Possible side effects from using WEGOVY®.
  • Driving and using machines

    • If you use this medicine in combination with certain diabetes medications (e.g. sulfonylurea or insulin), low blood sugar may occur which may reduce your ability to concentrate or make you feel dizzy. Avoid driving or using machines if you feel dizzy or unable to concentrate. Talk to your healthcare professional for further information.
  • Low blood sugar (hypoglycemia)

    • If you are taking certain diabetes medication (e.g. sulfonuylurea or insulin) when you start taking WEGOVY®, this could result in low blood sugar levels. Your healthcare professional may ask you to test your blood sugar levels. This will help your healthcare professional decides if the dose of your diabetes medication needs to be changed.
  • Effects on the digestive system and dehydration

    • During treatment with WEGOVY®, you may experience feeling sick (nausea) or being sick (vomiting), and diarrhea. These side effects can cause dehydration (loss of fluids). It is therefore important to drink plenty of fluids to prevent dehydration. This is especially important if you have kidney problems. Talk to your healthcare professional if you have any questions or concerns.
  • Severe stomach or gut problem resulting from delayed stomach emptying (gastroparesis).

    • If you have slow (delayed) stomach emptying (called gastroparesis), use of WEGOVY® may lead to serious or severe gastrointestinal adverse events. WEGOVY® is not recommended if you have severe gastroparesis.
    • Food or liquid getting into lungs during anaesthesia or sedation. Some patients taking medicines like WEGOVY® have had problems with food or liquid from their stomach getting into their lungs while under general anaesthesia or sedation. Tell your healthcare professional that you are taking WEGOVY® before you have a procedure that requires general anaesthesia or sedation.
  • Severe and on-going stomach pain which could be due to inflammation of the pancreas

    • If you have severe and on-going pain in the stomach area – see a healthcare professional straight away as this could be a sign of acute pancreatitis (inflamed pancreas).
  • Diabetic eye disease (retinopathy)

    • This medication may cause a temporary worsening of diabetic eye disease. If you have diabetic eye disease and experience eye or vision problems while taking this

      • medication, talk to your health care professional.
  • Sudden changes to your eyesight

    • If you notice a sudden loss of vision or rapidly worsening eyesight during treatment with this medicine, urgently contact your doctor. This may be caused by a very rare side effect called non-arteritic anterior ischaemic optic neuropathy (NAION). Your doctor will refer you for an eye examination by an ophthalmologist and you may have to stop treatment with this medicine.
  • Children and adolescents

    • WEGOVY® is not recommended for weight management in children and adolescents under 12 years of age or less than 60 kg (132 lbs) as the safety and efficacy in this age and weight group have not yet been studied.
    • WEGOVY® is not recommended in children and adolescents for reduction of non-fatal myocardial infarction as the safety and efficacy in this population has not yet been studied.
    • WEGOVY® is not recommended in children and adolescents with MASH as the safety and efficacy in this population has not yet been studied.
  • Pregnancy and breastfeeding

    • Tell your healthcare professional if you are pregnant, think you might be pregnant, or are planning to become pregnant. WEGOVY® should not be used during pregnancy and for at least two months before a planned pregnancy because it is not known if it may affect your unborn child. If you could become pregnant while using WEGOVY®, it is recommended to use contraception.
    • Do not use this medicine if you are breast-feeding. This is because it is not known if WEGOVY® passes into breast milk.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

People with Diabetes

In particular, tell your healthcare professional, pharmacist or nurse if you are using medicines containing any of the following:

  • sulfonylurea
  • insulin

Do not use WEGOVY® as a substitute for insulin.

The following may interact with WEGOVY®:

The following list includes some, but not all, of the drugs that may increase your heart rate. You should check with your healthcare professional or pharmacist before taking any other medication with WEGOVY®:

  • Drugs to treat hypertension.
  • Drugs to treat heart failure.
  • Drugs to treat HIV infection.
  • Drugs to treat attention deficit-hyperactivity disorder.
  • Drugs to suppress appetite/cause weight loss.
  • Decongestants.
  • Drugs to treat asthma.

How to take WEGOVY®

WEGOVY® is given as an injection under the skin (subcutaneous injection). Do not inject it into a vein or muscle. The best places to give the injection are the front of your thighs, the front of your waist (abdomen), or your upper arm.

Before you use the pen for the first time, your healthcare professional will show you how to use it.

Detailed instructions for use are on the other side of this leaflet.

Always use this medicine exactly as your health care professional has told you. Check with your healthcare professional, pharmacist or nurse if you are not sure.

You should use WEGOVY® once a week on the same day each week if possible. You can give yourself the injection at any time of the day – regardless of meals. To help you remember to inject WEGOVY® once a week only, it is recommended to note the chosen day of the week (e.g. Wednesday) on the carton.

If necessary, you can change the day of your weekly injection of WEGOVY® as long as it has been at least 3 days since your last injection of WEGOVY®.

Your healthcare professional should start you on a reduced calorie meal plan and physical activity program when you start taking WEGOVY®. Stay on this program while you are taking WEGOVY®.

Usual dose:

Adults

The recommended dose is 2.4 mg once weekly.

Your treatment will start at a low dose which will be gradually increased over 16 weeks of treatment.

  • When you first start taking WEGOVY®, the starting dose is 0.25 mg once weekly
  • Your healthcare professional will instruct you to gradually increase your dose every 4 weeks until you reach the recommended dose of 2.4 mg once weekly.

You will be told to follow the table below.

Dose escalationWeekly Dose
Week 1 – 40.25 mg
Week 5 – 80.5 mg
Week 9 – 121 mg
Week 13 – 161.7 mg
Maintenance Dose2.4 mg
  • Once you reach the recommended dose 2.4 mg, keep using this dose. Do not increase your dose further.

Your healthcare professional will assess your treatment on a regular basis and may tell you to change your dose if necessary.

Do not stop using this medicine without talking to your healthcare professional.

Adolescents

For adolescents aged 12 to less than 18 years, the same dose escalation schedule as for adults should be applied (see above). Adolescents should aim at reaching the 2.4 mg maintenance dose, but can stay at a lower dose if the 2.4 mg dose cannot be reached or is not tolerated.

Overdose:

If you use more WEGOVY® than you should, talk to your healthcare professional straight away. You may get side effects such as feeling sick (nausea) or being sick (vomiting), or diarrhea, or hypoglycemia (dizziness, confusion, passing out).

If you think you, or a person you are caring for, have taken too much WEGOVY®, contact a healthcare professional, hospital emergency department, regional poison control centre or Health Canada’s toll-free number, 1-844 POISON-X (1-844-764-7669) immediately, even if there are no signs or symptoms.

Missed Dose:

If you forgot to inject a dose and:

  • It is 5 days or less since you should have used WEGOVY®, use it as soon as you remember. Then inject your next dose as usual on your scheduled day.
  • It is more than 5 days since you should have used WEGOVY®, skip the missed dose. Then inject your next dose as usual on your scheduled day.

Do not take a double dose to make up for a missed dose.

Possible side effects from using WEGOVY®:

These are not all the possible side effects you may feel when taking WEGOVY®. If you experience any side effects not listed here, contact your healthcare professional.

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Very common: may affect more than 1 in 10 people

  • feeling or being sick (nausea or vomiting)
  • diarrhea
  • constipation
  • stomach pain
  • feeling weak or tired
  • headache

These usually goes away over time

Common: may affect up to 1 in 10 people

  • feeling dizzy
  • upset stomach or indigestion
  • burping
  • gas (flatulence)
  • bloating of the stomach
  • inflamed stomach (‘gastritis’) – the signs include stomach-ache, feeling sick (nausea) or being sick (vomiting)
  • reflux or heartburn – also called ‘gastro-esophageal reflux disease’
  • hair loss
  • injection site reactions
  • low blood sugar (hypoglycaemia) in patients with diabetes
  • low blood pressure
  • increase of pancreatic enzymes (such as lipase) shown in blood tests
  • hemorrhoids
  • change in the way food or drink tastes

The warning signs of low blood sugar may come on suddenly. They can include: cold sweat, cool pale skin, headache, fast heartbeat, feeling sick (nausea) or very hungry, changes in vision, feeling sleepy or weak, feeling nervous, anxious or confused, difficulty concentrating or shaking.

Your healthcare professional will tell you how to treat low blood sugar and what to do if you notice these warning signs.

Low blood sugar is more likely to happen if you also take a sulfonylurea or insulin. Your healthcare professional may reduce your dose of these medicines before you start using this medicine.

Uncommon: may affect up to 1 in 100 people

  • fast heartbeat
  • increase of pancreatic enzymes (such as amylase) shown in blood tests
  • feeling faint or fainting/passing out
  • low blood sugar (hypoglycemia) in patients without diabetes

Unknown:

  • bowel obstruction
  • ileus: A condition where your intestine can’t push food and waste out of your body (can cause severe constipation, with additional symptoms such as stomach ache, bloating, vomiting, etc)
  • a delay in the emptying of the stomach
  • change in skin sensation (e.g. sensitive skin, skin pain, unpleasant and abnormal feeling when touched, feeling of pins and needles including tingling, pricking or burning feeling in the skin)

Serious side effects and what to do about them

Frequency/ Side Effect/ SymptomTalk to your healthcare professionalStop taking this drug and get immediate medical help
Only if severeIn all cases
Common
Patients with Type 2 Diabetes – Diabetic retinopathy complications (complications of diabetic eye disease/diabetic eye problems): blurred vision,√
fluctuating vision, loss of vision, impaired colour vision.

Gallstones (solid lumps that form in the gallbladder):

sudden pain in the upper stomach or back, often on the right, nausea, vomiting, indigestion, or cramping

√√
Uncommon
Pancreatitis (inflammation of the pancreas): severe and ongoing pain in the stomach area√√
Patients with Type 2 Diabetes – Severe hypoglycemia (low blood sugar): feeling confused, fits and passing out√
Appendicitis (inflammation of the appendix): sudden pain in the middle or lower right side of the abdomen, chills, fever, nausea, vomiting√√
Acute kidney injury (sudden decrease in kidney function): swelling in the legs, ankles and feet, feeling tired, confusion, shortness of breath, not enough urine√√
Rare
Severe allergic reaction/ anaphylactic reaction/ angioedema) (sudden and intense response by the immune system): breathing problems, swelling of face, lips, tongue and/or throat with difficulty swallowing, and a fast heartbeat√√
Very Rare
Non-arteritic anterior ischemic optic neuropathy (sudden vision loss, may be painless, from swelling of eye nerves): blurring or cloudiness of vision, headaches√√

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

  • Visiting the Web page on Adverse Reaction Reporting (canada.ca/drug-device-reporting) for information on how to report online, by mail or by fax; or
  • Calling toll-free at 1-866-234-2345.

NOTE: Contact your healthcare professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Keep out of reach and sight of children.

Do not use this medicine after the expiry date which is stated on the pen label and carton after ʻEXP’. The expiry date refers to the last day of that month.

Keep away from the cooling element of the refrigerator. Do not freeze WEGOVY® and do not use WEGOVY® if it has been frozen. Protect from excessive heat and light.

WEGOVY® pen is for use by one person only.

WEGOVY® should not be used if it does not appear clear and colourless.

Do not dispose of any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help protect the environment.

Single-Use Pen

Store the WEGOVY® single-use pen in the refrigerator at 2°C to 8°C. If needed, each single-use pen, prior to cap removal, can be kept at a temperature below 30°C for a total of 28 days.

If your pen has been exposed to light or temperatures above 30°C, has been out of the refrigerator for more than 28 days, or has been frozen, dispose of it.

Storage of WEGOVY® single-use pen in the original carton is recommended until time of administration in order to protect from light.

Safely discard the WEGOVY® single-use pen into a sharps disposal container after use. Do not dispose of the pen in your household trash.

Multi-Use Pen

When you are not using the pen, keep the pen cap on in order to protect from light.

Before Opening:

Store in a refrigerator (2°C – 8°C).

During Use:

You can keep the pen for 8 weeks when stored at a temperature below 30°C or in a refrigerator (2°C – 8°C).

If your pen has been exposed to temperatures above 30°C, has been out of the refrigerator for more than 8 weeks, or has been frozen, dispose of it.

Always remove the injection needle after each injection and store the pen without a needle attached. This may prevent blocked needles, contamination, infection, leakage of solution and inaccurate dosing.

If you want more information about WEGOVY®:

  • Talk to your healthcare professional
  • Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada Drug Product Database website (Drug Product Database: Access the database); the manufacturer’s website www.novonordisk.ca, or by calling 1-800-465-4334.

Date of Authorization: 2026-10-02

WEGOVY®, NovoFine®, NovoFine® Plus and Novo Nordisk are trademarks of Novo Nordisk A/S and used under license by Novo Nordisk Canada Inc.

© 2026

Novo Nordisk Canada Inc.

Instructions for Use

WEGOVY® multi-use pre-filled pen (FlexTouch®)

Before using your once-weekly WEGOVY® pen, read these instructions carefully, and talk to your healthcare professional, nurse or pharmacist about how to inject WEGOVY® correctly.

WEGOVY® pen is a multi-use pen that contains four of your prescribed doses of WEGOVY®, corresponding to four times of once-weekly use.

Please use the table on the back of the carton to keep track of how many injections you have taken and how many doses remain in your pen.

WEGOVY® comes in five different strengths, each containing one of the following prescribed doses of semaglutide:

Always start by checking your pen label to make sure that it contains your prescribed dose of WEGOVY®.

Your pen is designed to be used with NovoFine® Plus or NovoFine® disposable needles up to a length of 8 mm.

The pack contains:

  • WEGOVY® pen
  • 4 disposable needles
  • Leaflet
  • Important information

Read this Instructions for Use before you start using WEGOVY®. This information does not replace talking to your healthcare provider about your medical condition or treatment.

  • Only inject one dose of WEGOVY® once weekly. If you do not take your WEGOVY® as prescribed, you may not get the intended effect of this medicine.
  • If you take more than one type of injectable medicine, it is very important to check the name and dose of your pen label before use.
  • Do not use this pen without help if you have poor eyesight and cannot follow these instructions. Get help from a person with good eyesight who is trained to use the WEGOVY® pen.
  • Always keep pen and needles out of sight and reach of others, especially children.
  • Never share your pen or your needles with other people.
  • Needles are for single use only. Never reuse your needles as it may lead to blocked needles, contamination, infection and inaccurate dosing.
  • Caregivers must be very careful when handling used needles to prevent accidental needle injuries and infection.
WEGOVY® pen (example)
Please note: Your pen may differ in size from the pen shown in the pictures. These instructions apply to all WEGOVY® pens.
Wegovy® pen (example) Please Note: Your pen may differ in size from the pen shown in the pictures. These instructions apply to all Wegovy® pens. Pen cap Pen window Dose counter Dose pointer Dose selector Dose button Expiry date (EXP) on back of pen label EXP: LOT:

Disposable needle (example)

Outer needle cap Inner needle cap Needle Paper tab Disposable needle (example)

1 Prepare your pen with a new needle

Check the name and dose of your pen to make sure it contains your prescribed dose of WEGOVY®.

Pull off the pen cap.

A
Check that the WEGOVY® in your pen is clear and colourless. Look through the pen window. If the solution looks cloudy or coloured, do not use the pen.B

Always use a new needle for each injection.

Take a needle when you are ready to take your injection. Check the paper tab and the outer needle cap for damages. If you see any damage, this could affect sterility. Dispose of it and use a new needle.

Tear off the paper tab.

C
Push the needle straight onto the pen. Turn until it is on tight.D

The needle is covered by two caps. You must remove both caps. If you forget to remove both caps you will not inject any medicine.

Pull off the outer needle cap and keep it for later. You will need it to safely remove the needle from the pen after the injection.

Pull off the inner needle cap and dispose of it. A drop of solution may appear at the needle tip. You must still check the flow if you use a new pen for the first time. See ‘Check the flow with each new pen’.

Never use a bent or damaged needle. For more information about needle handling, see ‘About your needles’ below these instructions.

E
Check the flow with each new pen

If your pen is already in use, go to ‘2 Set your dose’.

Only check the flow before your first injection with each new pen.

Turn the dose selector until you see the flow check symbol ( ).

F
Make sure the flow check symbol lines up with the dose pointer.G

Hold the pen with the needle pointing up.

Press and hold in the dose button until the dose counter returns to . The must line up with the dose pointer.

A drop of solution should appear at the needle tip. This drop indicates that your pen is ready for use.

If a drop does not appear, check the flow again. This should only be done twice.

If there is still no drop, change the needle and check the flow once more. If a drop still does not appear, dispose of the pen and use a new one.

H
2 Set your dose
Turn the dose selector until the dose counter stops, and it shows your prescribed dose.I

The dashed line ( ) in the dose counter will guide you to your dose.

The dose selector clicks differently when turned forward, backwards or past your dose. You will hear a ‘click’ every time you turn the dose selector. Do not set the dose by counting the number of clicks you hear.

J Dashed line

When your prescribed dose lines up with the dose pointer, you have selected your dose. In this picture, the dose is shown as an example.

If the dose counter stops before you reach your prescribed dose, see the section ‘Do you have enough WEGOVY®?’ below these instructions.

K Example: 0.25 mg selected

Choose your injection site

Choose upper arms, stomach or upper legs (keep a 5 cm distance from your belly button).

You may inject in the same body area each week, but make sure it is not in the same spot as used the last time.

Upper arms Stomach Upper legs
3 Inject your dose

Insert the needle into your skin as your healthcare professional has shown you.

Make sure you can see the dose counter. Do not cover it with your fingers. This could interrupt the injection.

Press and hold down the dose button until the dose counter shows .

Keep pressing the dose button with the needle in your skin and slowly count to 6. The must line up with the dose pointer. You may hear or feel a click when the dose counter returns to .

M

N Count slowly 1-2-3-4-5-6

L

Remove the needle from your skin. If the needle is removed earlier, a stream of solution may come from the needle tip and the full dose will not be delivered.

If blood appears at the injection site, press lightly on the area to stop the bleeding.

You may see a drop of solution at the needle tip after injecting. This is normal and does not affect your dose.

O
4 After your injection

Lead the needle tip into the outer needle cap on a flat surface without touching the needle or the outer needle cap.

Once the needle is covered, carefully push the outer needle cap completely on.

P

Unscrew the needle and dispose of it carefully as instructed by your healthcare professional, nurse, pharmacist or local authorities.

Never try to put the inner needle cap back on the needle. You may stick yourself with the needle.

Always dispose of the needle immediately after each injection to prevent blocked needles, contamination, infection and inaccurate dosing. Never store your pen with the needle attached.

Q
Put the pen cap on your pen after each use to protect the solution from light.R

When the pen is empty, dispose of it without a needle on as instructed by your healthcare professional, nurse, pharmacist or local authorities.

The pen cap and the empty carton can be disposed of in your household waste.

About your needles

How to identify a blocked or damaged needle

  • If does not appear in the dose counter after continuously pressing the dose button, you may have used a blocked or damaged needle.
  • In this case, you have not received any medicine – even though the dose counter has moved from the original dose that you have set.

How to handle a blocked needle

  • Change the needle as instructed in ‘1 Prepare your pen with a new needle’ and go to ‘2 Set your dose’.
Caring for your pen

Treat your pen with care. Rough handling or misuse may cause inaccurate dosing. If this happens, you might not get the intended effect of WEGOVY®.

  • See the back of this leaflet to read the storage conditions for your pen.
  • Do not leave the pen in a car or another place where it can get too hot or too cold.
  • Do not inject WEGOVY® that has been exposed to direct sunlight.
  • Do not subject WEGOVY® to frost and never inject WEGOVY® that has been frozen. Dispose of the pen.
  • Do not drop your pen or knock it against hard surfaces.
  • Do not try to refill your pen. Once empty, it must be disposed of.
  • Do not try to repair your pen or pull it apart.
  • Do not expose your pen to dust, dirt or liquid.
  • Do not wash, soak or lubricate your pen. If necessary, clean it with a mild detergent on a moistened cloth.
Do you have enough WEGOVY®?
If the dose counter stops before you reach your prescribed dose, there is not enough medicine left for a full dose. Dispose of the pen and use a new WEGOVY® pen.

Instructions for Use

WEGOVY® single-use pre-filled pen

semaglutide injection

WEGOVY® comes in five strengths:

Use WEGOVY® 1 time each week

Before you use your WEGOVY® pen for the first time, talk to your healthcare professional or your caregiver about how to prepare and inject WEGOVY® correctly.

Pull out to get started

Important information

Read this Instructions for Use before you start using WEGOVY®. This information does not replace talking to your healthcare professional about your medical condition or treatment.

  • Your WEGOVY® pen is for 1 time use only. The WEGOVY® pen is for subcutaneous (under the skin) use only.
  • The dose of WEGOVY® is already set on your pen.
  • The needle is covered by the needle cover and the needle will not be seen.
  • Do not remove the pen cap until you are ready to inject.
  • Do not touch or push on the needle cover. You could get a needle stick injury.
  • Your WEGOVY® injection will start when the needle cover is pressed firmly against your skin.
  • During dosing, a yellow bar will appear in the pen window.
  • Do not remove the pen from your skin before the yellow bar in the pen window has stopped moving. If the pen is removed too early or if you have not pressed the pen firmly against the skin for the entire injection, medication may appear on the skin or squirt from the needle and you may not get your full dose of WEGOVY®.
  • If the yellow bar does not start moving or stops during the injection, contact your healthcare provider.
  • The needle cover will lock when the pen is removed from your skin. You cannot stop the injection and restart it later.
  • People who are blind or have vision problems should not use the WEGOVY® pen without help from a person trained to use the WEGOVY® pen.

Before use After use Wegovy® pen parts Expiration date (on the back) Check that Wegovy® has not expired Always check you have the medicine and dose that your healthcare provider prescribed. Either: Pen window Check that Wegovy® is clear and colorless. Air bubbles are normal. They do not affect your dose. Needle cover Needle is hidden inside Pen cap Remove it just before you are ready to inject Pen window Check that the yellow bar has stopped moving to make sure you received your full dose Needle cover locks after use 0.25 mg / 0.5 mL 0.5 mg / 0.5 mL 1 mg / 0.5 mL 2.4 mg / 0.75 mL 1.7 mg / 0.75 mL

How to use your WEGOVY® pen

Do not use your WEGOVY® pen without receiving training from your healthcare professional. Make sure that you or your caregiver know how to give an injection with the pen before you start your treatment.

Read and follow the instructions so that you use your WEGOVY® pen correctly:

Preparation

Step 1. Prepare for your injection.

  • Supplies you will need to give your WEGOVY® injection: your WEGOVY® pen, 1 gauze pad or cotton ball, 1 sharp disposable container for used WEGOVY® pens.
  • Wash your hands.
  • Check your WEGOVY® pen.

Do not use your WEGOVY® pen if:

  • The pen appears to have been used or any part of the pen appears broken, for example if it has been dropped.
  • The WEGOVY® medicine looks cloudy through the pen window.
  • The expiration date (Expiry) has passed.

Step. 2 Choose your injection site.

  • Choose your upper arms, upper legs (front of the thighs) or lower stomach (keep 2 inches away from your belly button).
  • Do not inject into an area where the skin is tender, bruised, red, or hard. Avoid injecting into areas with scars or stretch marks.
  • You may inject in the same body area each week, but make sure it is not in the same spot each time.

Clean the injection site. Do not touch the injection site after cleaning.

Upper arms Stomach Upper legs

Injection

Step 3. Remove pen cap.

  • Pull the pen cap straight off your pen.

Step 4. Inject WEGOVY®.

Push the pen firmly against your skin and keep applying pressure until the yellow bar has stopped moving.

  • If the yellow bar does not start moving, press the pen more firmly against your skin.

What if blood appears after injection?

If blood appears at the injection site, press lightly with a gauze pad or cotton ball.

Pen cap Click 1 The injection starts. Keep applying pressure until the yellow bar has stopped moving. Click 2 Yellow bar has stopped moving. The injection is complete. Lift the pen slowly. The injection takes about 5-10 seconds Injection Step 3. Remove pen cap. • Pull the pen cap straight off your pen. Step 4. Inject Wegovy®. Push the pen firmly against your skin and keep applying pressure until the yellow bar has stopped moving. • If the yellow bar does not start moving, press the pen more firmly against your skin. What if blood appears after injection? If blood appears at the injection site, press lightly with a gauze pad or cotton ball. Disposal Step 5. Dispose of pen. Safely dispose of the pen right away after use. S “H d I r y d p f Wegovy® p ?”

  • If you experience difficulties injecting, change to a more firm injection site, such as upper leg, or upper arm or consider standing up while injecting into the lower stomach.
  • If medication appears on the skin or squirts from the needle, make sure the next time you inject to keep applying pressure until the yellow bar has stopped moving. Then you can lift the pen slowly from your skin.

Medication

How do I dispose of WEGOVY® pens?

  • Put the WEGOVY® pen in a closeable, puncture-resistant sharps disposal container.
  • Do not dispose of the pen in your household trash.
  • Do not reuse the pen.
  • Do not recycle the pen or sharps disposal container, or throw them into household trash.
  • Ask your healthcare provider about options available in your area to dispose of the sharps container properly.
  • The directions regarding pen handling and disposal are not intended to replace local, healthcare provider or institutional policies.
  • Important: Keep your WEGOVY® pen, sharps disposal container and all medicines out of the reach of children.

    How do I care for my pen?

Protect your pen

  • Do not drop your pen or knock it against hard surfaces.
  • Do not expose your pen to any liquids.
  • If you think that your pen may be damaged, do not try to fix it. Use a new one.
  • Keep the pen cap on until you are ready to inject. Your pen will no longer be sterile if you store an unused pen without the cap, if you pull the pen cap off and put it on again, or if the pen cap is missing. This could lead to an infection.

How do I store WEGOVY®?

  • Store the WEGOVY® pen in the refrigerator between 2°C to 8°C.
  • Keep WEGOVY® in the original carton to protect it from light.
  • If needed, WEGOVY® may be stored at a temperature below 30°C in the original carton for up to 28 days.
  • Do not freeze.
  • Dispose of the pen if WEGOVY® has been frozen, has been exposed to light or temperatures above 30°C, or has been out of the refrigerator for 28 days or longer.

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 02522551

Approved according to the text: October 2, 2026

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Wegovy

Rx or OTC
Prescription (Rx)?
DIN 02522551, 02522578, 02522586, 02522594, 02522608, 02528509, 02528517, 02528525, 02528533, 02528541, 02552698
Schedule(s) PRESCRIPTION; SCHEDULE D
Active ingredient(s) Semaglutide
Dosage form(s) Solution
Route(s) of administration Subcutaneous
Drug class (WHO ATC)
  1. A Alimentary tract and metabolism drugs
    1. A10 Drugs used in diabetes
      1. A10B Blood glucose lowering drugs, excl. insulins
        1. A10BJ Glucagon-like peptide-1 (GLP-1) analogues
          1. A10BJ06 Semaglutide
Company NOVO NORDISK CANADA INC
Strengths and forms
DIN Strength Dosage form(s) Current status
02522551 0.25 MG Solution Approved November 23, 2021
02522578 0.5 MG Solution Approved November 23, 2021
02522586 1 MG Solution Approved November 23, 2021
02522594 1.7 MG Solution Approved November 23, 2021
02522608 2.4 MG Solution Approved November 23, 2021
02528509 1 MG Solution Marketed March 28, 2024
02528517 2 MG Solution Marketed April 2, 2024
02528525 4 MG Solution Marketed March 28, 2024
02528533 6.8 MG Solution Marketed April 2, 2024
02528541 9.6 MG Solution Marketed April 22, 2024
02552698 2 MG Solution Marketed August 27, 2026

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.